[Clinical significance of tumor content of epidermal growth factor receptor in breast cancer].

Autor:	Mulero M; Medicina de Familia y Comunitaria del Hospital Central de Asturias. Oviedo. Asturias. Spain., Fernández Raigoso P, Vázquez J, Lamelas ML, Corte D, Allende MT, Rodríguez JC, Vizoso F
Jazyk:	Spanish; Castilian
Zdroj:	Revista espanola de medicina nuclear [Rev Esp Med Nucl] 2003 Nov; Vol. 22 (6), pp. 386-94.
DOI:	10.1016/s0212-6982(03)72222-8
Abstrakt:	Objective: To determine the content of epidermal growth factor receptor (EGFR) using a radioligand method in breast cancer and to analyze the relationship between the EGFR levels and the characteristics of patients and tumors. Prognostic significance was also analyzed. Material and Methods: EGFR was measured by a single point radioligand assay in 265 invasive breast carcinomas tissues. In addition, estrogen and progesterone receptors (ER and PR) were measured by enzymatic immunoassays. We analyze the relationship of EGFR levels with the different clinico-pathologic parameters. Results: EGFR levels in breast carcinomas varied widely (0.1 to 403) with a median at 4 fmol/mg prot. The significantly higher concentrations of EGFR were detected in patients under 60 years old (p = 0.042), undifferentiated tumors (p = 0.04), and carcinomas with negative ER and PR (p < 0.019 y p < 0018, respectively). In addition, there was a negative correlation between EGFR and the ER and PR levels (p < 0.05). EGFR levels did not show any relationship with the patient's prognosis. Conclusions: In addition, intratumoral levels of EGFR in breast carcinomas vary widely and the highest concentrations are associated with the most aggresive characteristics of the tumor.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu